Role of the NLRP3 inflammasome in gynecological disease

Xu Zheng, Dan Zhao, Ye Jin, Yang Liu, Da Liu
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023 · vol. 166 , pp. 115393 · doi:10.1016/j.biopha.2023.115393 · PMID:37660654 · W4386407492
review OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

Abstract

The NLR family pyrin domain containing 3 (NLRP3) inflammasome is involved in the innate immune system and is a three-part macromolecular complex comprising the NLRP3 protein, apoptosis-associated speck-like protein containing a CARD (ASC) and the cysteine protease pro-caspase-1. When the NLRP3 inflammasome is activated, it can produce interleukin (IL)- 1β and IL-18 and eventually lead to inflammatory cell pyroptosis. Related studies have demonstrated that the NLRP3 inflammasome can induce an immune response and is related to the occurrence and development of gynecological diseases, such as endometriosis, polycystic ovary syndrome and breast cancer. NLRP3 inflammasome inhibitors are beneficial for maintaining cellular homeostasis and tissue health and have been found effective in targeting some gynecological diseases. However, excessive inhibitor concentrations have been found to cause adverse effects. Therefore, proper control of NLRP3 inflammasome activity is critical. This paper summarizes the structure and function of the NLRP3 inflammasome and highlights the therapeutic potential of targeting it in gynecological diseases, such as endometriosis, polycystic ovary syndrome and breast cancer The application of NLRP3 inflammasome inhibitors is also discussed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic Ovary Syndrome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-19T00:33:17.497793+00:00
License: CC0 · commercial use OK